Agios Pharmaceuticals, Inc.

Historical 13F Holders

Symbol
AGIO
CUSIP
00847X104
All holders as of
Q3 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Shares Held, Excluding Options
Total Filers

13D/G Filers

Each filer's latest filing for 00847X104 since 12/18/2024, largest first.

Filer % of Class Filed
Farallon Capital Management, L.L.C. 13G/A
9.9% 8/3/2026
Event 6/30/2026
Farallon Capital Partners, L.P. 13G/A
8.8% 2/9/2026
Event 12/31/2025
BlackRock, Inc. 13G/A 7.8% 7/17/2025
Event 6/30/2025
D. E. Shaw & Co., L.P. 13G/A
6.5% 11/16/2026
Event 9/30/2026
Morgan Stanley 13G 5.7% 11/13/2026
Event 9/30/2026
State Street Corp 13G 5.3% 2/9/2026
Event 12/31/2025
Vanguard Capital Management LLC 13G 5.3% 4/29/2026
Event 3/31/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (6)
Paradigm Biocapital Advisors LP 13G/A
4.9% 11/14/2025
Event 9/30/2025
Armistice Capital, LLC 13G/A
4.6% 5/15/2026
Event 3/31/2026
Lynx1 Capital Management LP 13G/A
0.8% 11/16/2026
Event 9/30/2026
BB Biotech AG 13G/A
0% 6/13/2025
Event 6/1/2025
Bellevue Group AG 13G/A
0% 12/5/2025
Event 11/19/2025
Vanguard Group Inc 13G/A 0% 3/26/2026
Event 3/13/2026

13F Holders by Quarter

Period Filers Shares, Excl. Options Value, Excl. Options
2026 Q3 244 67.3 M $2.24B
2026 Q2 239 66.0 M $2.45B
2026 Q1 238 63.1 M $2.12B
2025 Q4 241 61.3 M $1.67B
2025 Q3 228 63.5 M $2.55B
2025 Q2 219 61.7 M $2.05B
2025 Q1 223 60.1 M $1.76B
2024 Q4 229 59.8 M $1.97B
2024 Q3 213 58.1 M $2.58B
2024 Q2 210 58.2 M $2.51B
2024 Q1 192 62.0 M $1.81B
2023 Q4 172 59.9 M $1.33B
2023 Q3 151 59.1 M $1.46B
2023 Q2 156 59.4 M $1.68B
2023 Q1 167 59.0 M $1.36B
2022 Q4 165 59.5 M $1.67B
2022 Q3 171 58.0 M $1.64B
2022 Q2 159 59.0 M $1.31B
2022 Q1 162 59.9 M $1.74B
2021 Q4 165 59.2 M $1.95B
2021 Q3 169 60.9 M $2.81B
2021 Q2 191 65.9 M $3.63B
2021 Q1 182 65.3 M $3.37B
2020 Q4 206 65.0 M $2.82B
2020 Q3 218 65.9 M $2.30B
2020 Q2 220 67.5 M $3.61B
2020 Q1 202 69.4 M $2.47B
2019 Q4 205 69.0 M $3.30B
2019 Q3 192 61.9 M $2.01B
2019 Q2 193 60.8 M $3.03B
2019 Q1 207 60.1 M $4.06B
2018 Q4 200 58.1 M $2.68B
2018 Q3 213 56.0 M $4.32B
2018 Q2 220 54.9 M $4.63B
2018 Q1 200 54.9 M $4.48B
2017 Q4 181 47.0 M $2.69B
2017 Q3 174 46.1 M $3.07B
2017 Q2 171 46.2 M $2.37B
2017 Q1 160 41.0 M $2.39B
2016 Q4 165 39.1 M $1.63B
2016 Q3 165 37.9 M $2.00B
2016 Q2 158 34.1 M $1.42B
2016 Q1 159 33.8 M $1.37B
2015 Q4 145 33.0 M $2.14B
2015 Q3 153 31.4 M $2.22B
2015 Q2 162 30.1 M $3.35B
2015 Q1 152 28.0 M $2.64B
2014 Q4 145 27.7 M $3.10B
2014 Q3 120 24.5 M $1.50B
2014 Q2 99 23.6 M $1.08B
2014 Q1 75 20.5 M $804M